Literature DB >> 8366734

[Inguinal recurrence after therapeutic lymphadenectomy in malignant melanoma].

L Kretschmer1, C Lautenschläger, K P Preusser, H Fiedler.   

Abstract

In a retrospective study, 73 stage-II melanoma patients with 22 superficial and 51 deep groin dissections were observed over a maximum of 9 years of follow up (median 67.5 months). The 5-year survival rate of 29.8% was consistent with that yielded by comparable analyses of other investigators. However, the probability of recurrence in the node dissection field was as high as 35%. All groin recurrences occurred in the first 29 months after lymph node clearance (median 6 months). Patients with groin recurrence following lymph-node dissection had a poor prognosis (median survival 12 months). In a multifactorial analysis (Cox model), the only prognostic factor of probability of recurrence was the development of regional in-transit cutaneous metastases (p = 0.0028). Factors that did not affect the appearance of recurrent metastases in the node dissection field were: site of primary melanoma, tumor thickness, epidermal ulceration, degree of lymph node involvement (p = 0.2) age, sex, degree of surgery (superficial or deep groin dissection) and adjuvant chemotherapy. Because regional in-transit cutaneous metastases mostly occur synchronously with groin recurrence or later, they are a typical concomitant phenomenon rather than a prognostic factor of recurrence.

Entities:  

Mesh:

Year:  1993        PMID: 8366734     DOI: 10.1007/bf00184363

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  20 in total

1.  Malignant melanoma of the skin; report of 341 cases treated during the years 1929-1943.

Authors:  B SYLVEN
Journal:  Acta radiol       Date:  1949-07-31       Impact factor: 1.990

2.  Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.

Authors:  T K Gupta
Journal:  Ann Surg       Date:  1977-08       Impact factor: 12.969

3.  Melanoma with metastasis to regional axillary or inguinal lymph nodes: prognostic factors and results of surgical treatment in 714 patients.

Authors:  S E Singletary; R Shallenberger; V F Guinee; C M McBride
Journal:  South Med J       Date:  1988-01       Impact factor: 0.954

4.  Extent of lymph node dissection in melanoma of the trunk or lower extremity.

Authors:  D G Coit; M F Brennan
Journal:  Arch Surg       Date:  1989-02

5.  "Prophylactic" lymph node dissection in melanoma: does it help?

Authors:  B Cady
Journal:  J Clin Oncol       Date:  1988-01       Impact factor: 44.544

6.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

7.  Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site.

Authors:  J H Wong; L A Cagle; D L Morton
Journal:  Arch Surg       Date:  1987-12

8.  [Axillary recurrence after lymph node excision in malignant melanoma].

Authors:  L Kretschmer; C Lautenschläger; K P Preusser; H Fiedler; I Hetschko
Journal:  Langenbecks Arch Chir       Date:  1993

9.  Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases.

Authors:  A Calabro; S E Singletary; C M Balch
Journal:  Arch Surg       Date:  1989-09

10.  Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes.

Authors:  C L Day; A J Sober; R A Lew; M C Mihm; T B Fitzpatrick; A W Kopf; M N Harris; S L Gumport; J W Raker; R A Malt; F M Golomb; A B Cosimi; W C Wood; P Casson; S Lopransi; F Gorstein; A Postel
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

View more
  1 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.